Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Severe gastrointestinal mucositis following high dose melphalan therapy for multiple myeloma.

Sharma SK, Handoo A, Choudhary D, Dhamija G, Gupta N.

World J Gastroenterol. 2013 Feb 7;19(5):784-5. doi: 10.3748/wjg.v19.i5.784.

2.

Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy--European Blood and Marrow Transplantation Mucositis Advisory Group.

Blijlevens N, Schwenkglenks M, Bacon P, D'Addio A, Einsele H, Maertens J, Niederwieser D, Rabitsch W, Roosaar A, Ruutu T, Schouten H, Stone R, Vokurka S, Quinn B, McCann S; European Blood and Marrow Transplantation Mucositis Advisory Group.

J Clin Oncol. 2008 Mar 20;26(9):1519-25. doi: 10.1200/JCO.2007.13.6028. Epub 2008 Feb 11.

PMID:
18268357
3.

Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model.

Grazziutti ML, Dong L, Miceli MH, Krishna SG, Kiwan E, Syed N, Fassas A, van Rhee F, Klaus H, Barlogie B, Anaissie EJ.

Bone Marrow Transplant. 2006 Oct;38(7):501-6.

PMID:
16980998
4.

Infusional mitoxantrone plus bolus melphalan as a stem cell transplant conditioning regimen for multiple myeloma.

Beaven AW, Moore DT, Sharf A, Serody JS, Shea TC, Gabriel DA.

Cancer Invest. 2011 Mar;29(3):214-9. doi: 10.3109/07357907.2010.550663.

PMID:
21314330
5.

A Phase IIb, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation.

Hari P, Aljitawi OS, Arce-Lara C, Nath R, Callander N, Bhat G, Allen LF, Stockerl-Goldstein K.

Biol Blood Marrow Transplant. 2015 Dec;21(12):2100-2105. doi: 10.1016/j.bbmt.2015.08.026. Epub 2015 Aug 29.

6.

Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients.

Carreras E, Rosiñol L, Terol MJ, Alegre A, de Arriba F, García-Laraña J, Bello JL, García R, León A, Martínez R, Peñarrubia MJ, Poderós C, Ribas P, Ribera JM, San Miguel J, Bladé J, Lahuerta JJ; Spanish Myeloma Group/PETHEMA.

Biol Blood Marrow Transplant. 2007 Dec;13(12):1448-54.

7.

Usefulness and safety of oral cryotherapy in the prevention of oral mucositis after conditioning regimens with high-dose melphalan for autologous stem cell transplantation for lymphoma and myeloma.

Batlle M, Morgades M, Vives S, Ferrà C, Oriol A, Sancho JM, Xicoy B, Moreno M, Magallón L, Ribera JM.

Eur J Haematol. 2014 Dec;93(6):487-91. doi: 10.1111/ejh.12386. Epub 2014 Jun 21.

PMID:
24889275
8.

Combined submyeloablative and myeloablative dose intense melphalan results in satisfactory responses with acceptable toxicity in patients with multiple myeloma.

Novitzky N, Thomson J, Thomas V, du Toit C, Mohamed Z, McDonald A.

Biol Blood Marrow Transplant. 2010 Oct;16(10):1402-10. doi: 10.1016/j.bbmt.2010.04.002. Epub 2010 Apr 10.

9.

Comparison of 1-day vs 2-day dosing of high-dose melphalan followed by autologous hematopoietic cell transplantation in patients with multiple myeloma.

Parmar SR, Bookout R, Shapiro JF, Tombleson R, Perkins J, Kim J, Yue B, Tomblyn M, Alsina M, Nishihori T.

Bone Marrow Transplant. 2014 Jun;49(6):761-6. doi: 10.1038/bmt.2014.56. Epub 2014 Mar 24.

PMID:
24662419
10.

Icing oral mucositis: Oral cryotherapy in multiple myeloma patients undergoing autologous hematopoietic stem cell transplant.

Chen J, Seabrook J, Fulford A, Rajakumar I.

J Oncol Pharm Pract. 2017 Mar;23(2):116-120. doi: 10.1177/1078155215620920. Epub 2016 Jul 9.

PMID:
26684614
11.

The Prospective Oral Mucositis Audit: relationship of severe oral mucositis with clinical and medical resource use outcomes in patients receiving high-dose melphalan or BEAM-conditioning chemotherapy and autologous SCT.

McCann S, Schwenkglenks M, Bacon P, Einsele H, D'Addio A, Maertens J, Niederwieser D, Rabitsch W, Roosaar A, Ruutu T, Schouten H, Stone R, Vorkurka S, Quinn B, Blijlevens N; EBMT Mucositis Advisory Group.

Bone Marrow Transplant. 2009 Jan;43(2):141-7. doi: 10.1038/bmt.2008.299. Epub 2008 Sep 8.

PMID:
18776926
12.

Mucositis not neutropenia determines bacteremia among hematopoietic stem cell transplant recipients.

Herbers AH, de Haan AF, van der Velden WJ, Donnelly JP, Blijlevens NM.

Transpl Infect Dis. 2014 Apr;16(2):279-85. doi: 10.1111/tid.12195. Epub 2014 Mar 13.

PMID:
24621081
13.

Engraftment syndrome after hematopoietic stem cell transplantation in multiple myeloma.

Katzel JA, Mazumder A, Jagannath S, Vesole DH.

Clin Lymphoma Myeloma. 2006 Sep;7(2):151. No abstract available.

PMID:
17026829
14.

Hepatic veno-occlusive disease after tandem autologous stem cell transplantation conditioned by melphalan.

Labidi SI, Sebban C, Ghesquières H, Nicolas EV, Biron P.

Int J Hematol. 2008 Oct;88(3):291-293. doi: 10.1007/s12185-008-0152-x. Epub 2008 Aug 12.

PMID:
18696182
15.

A phase I dose-escalation trial of high-dose melphalan with palifermin for cytoprotection followed by autologous stem cell transplantation for patients with multiple myeloma with normal renal function.

Abidi MH, Agarwal R, Tageja N, Ayash L, Deol A, Al-Kadhimi Z, Abrams J, Cronin S, Ventimiglia M, Lum L, Ratanatharathorn V, Zonder J, Uberti J.

Biol Blood Marrow Transplant. 2013 Jan;19(1):56-61. doi: 10.1016/j.bbmt.2012.08.003. Epub 2012 Aug 11.

16.

Impact of palifermin on mucosal toxicity in autologous stem cell transplants using busulfan-melphalan conditioning chemotherapy for Hodgkin and non-Hodgkin lymphoma.

Campbell P, Friebe A, Foulstone P, Grigg A, Hempton J, Bajel A.

Leuk Lymphoma. 2012 Jul;53(7):1415-6. doi: 10.3109/10428194.2011.653639. Epub 2012 Jan 31. No abstract available.

PMID:
22204452
17.

Intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: a matched comparison to a melphalan-only approach.

Blanes M, Lahuerta JJ, González JD, Ribas P, Solano C, Alegre A, Bladé J, San Miguel JF, Sanz MA, de la Rubia J.

Biol Blood Marrow Transplant. 2013 Jan;19(1):69-74. doi: 10.1016/j.bbmt.2012.08.009. Epub 2012 Aug 13.

18.

Reduced intensity conditioning with thiotepa, fludarabine, and melphalan is effective in advanced multiple myeloma.

Majolino I, Davoli M, Carnevalli E, Locasciulli A, Di Bartolomeo P, Scimè R, Corradini P, Selleri C, Narni F, Musso M, Bregni M, Olivieri A, De Fabritiis P, Pogliani L, Arbelaez JE, Ruscio C, Bacigalupo A; Gitmo Institutions.

Leuk Lymphoma. 2007 Apr;48(4):759-66.

PMID:
17454635
19.
20.

Bortezomib and high-dose melphalan conditioning for stem cell transplantation for AL amyloidosis: a pilot study.

Sanchorawala V, Quillen K, Sloan JM, Andrea NT, Seldin DC.

Haematologica. 2011 Dec;96(12):1890-2. doi: 10.3324/haematol.2011.049858. Epub 2011 Aug 22. No abstract available.

Supplemental Content

Support Center